MACNICA,-INC.
7.11.2016 11:02:05 CET | Business Wire | Press release
Macnica, Inc., a global leader in distributing semiconductors, electronic components, and network equipment, with its headquarter located in 1-6-3 Shin-Yokohama, Kohoku-ku, Yokohama, Japan (“Macnica”), today expanded its Mpression IP portfolio releasing SLVS-EC interface IP core for ALTERA FPGA compliant with SLVS-EC interface technology newly incorporated into Sony CMOS Image Sensor. Users can quickly develop and introduce their products early into market with SLVS-EC technology.
Macnica is a global, technology oriented distributor particularly focusing on demand creation. Macnica not only offers outstanding technical support for its product lines but also provides its original products and services under its “Mpression” brand for satisfying customer needs and solving issues.
Sony CMOS Image Sensor with SLVS-EC interface capable of high speed data
transfer will be introduced into CMOS Image Sensor market to satisfy
needs for trending higher resolution and higher framerate.
Mpression
SLVS-EC Rx IP Macnica has developed can support and contribute users who
develop advanced products supporting SLVS-EC interface.
Macnica has paid attention to SLVS-EC interface in the early days and
realized a world first solution to receive high speed image data
transmitted over SLVS-EC interface on ALTERA FPGA.
Now, the IP
enables to connect Sony high resolution and high framerate CMOS Image
Sensor to FPGA easily. It is ideal for a various applications like the
products with CMOS image sensor and FPGA to receive the image data.
Macnica is licensing the IP worldwide through its subsidiaries or
partners. ATD Electronique, an affiliate of Macnica sells and supports
it in Europe.
Macnica will exhibit demonstration of SLVS-EC Rx IP
at the booth of ATD Electronique in VISION SHOW held in Stuttgart,
Germany from November 8 to 10. Please don’t forget to visit us.
|
VISION SHOW Information |
||
| Name of Exhibition |
VISION
Leading world trade fair for machine vision |
|
| Schedule | 08 - 10 November 2016 | |
| Place | Messe Stuttgart | |
| Booth No. of ATD Electronique | Hall 1, E82 | |
* All company names and product names mentioned herein are trademarks or registered trademarks of their respective owners.
About Macnica:
Macnica has been established since 1972 as a semiconductor distribution company headquartered in Yokohama, Japan servicing customers in Japan, the Americas and Asia through its 75 sales offices around the world. Total number of employees is over 2,000 worldwide and total revenue for fiscal 2015 was approximately US$4B. Macnica is famous for having an excellent engineering team of more than 800 application engineers with strong focus on providing technical support for its customers. Macnica is continuing to improve its presence globally by having successful partners in strategic areas in the electronics market. Macnica Inc. and ATD Electronique have entered into an agreement for Macnica to acquire 49% of ATD’s outstanding shares on July 22nd, 2016.
About ATD Electronique:
ATD Electronique, who was founded in 1990 represents and distributes innovative electronic component brands and offers engineering services for machine vision and imaging applications through its offices in France and Germany and its representatives in Italy and Spain. Its product portfolio includes image sensors, controller & interface ICs, ISPs as well as development tools and design services enabling fast and efficient realization of new high performance camera systems for markets such as automotive, medical, security and machine vision.
About Mpression:
Mpression represents an integration and collection of all original
technology solutions of Macnica group such as software, platforms,
evaluation boards, and others which has been developed, provided and
supported in each country by each Macnica group companies.
Macnica
provides its advanced and ready-to-use system level solutions to
customers based on the accumulated know-hows by the very experienced
engineers from worldwide group companies, and thus leads to maximizing
the value of products as well as shortening customer's development time.
Macnica
is going to propose and support the IP offering one-stop services
through its group companies in all regions from country to country in
Europe, USA, China, and Asia.
Please visit our web-site (http://m-pression.com/
)
for a full detail of Mpression.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161107005041/en/
Contact:
Macnica, Inc.
Hajime Nakamura, 81-45-470-9838
Sales Planning,
Advanced Technology
AtdSpl@macnica.co.jp
FAX:
81-45-470-9857
Macnica Bldg No.2, 1-5-5 Shin-Yokohama, Kouhoku-ku,
Yokohama, 222-8563 JAPAN
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom